Tag Archives: CHKE

Best Value Stocks To Own Right Now

Northern Trust (NTRS Quick QuoteNTRS ) has launched an artificial intelligence (AI) powered tool to derive unstructured investment information from alternative asset documents, in a bid to further digitize its alternative asset servicing business. This underpins the company’s efforts to enhance its asset owner clients’ experience as well as abate operational risk in the alternative asset servicing business.

The proprietary solution has been built in collaboration with Microsoft Azure Applied AI Services, which hastens time to value for companies formulating AI solutions,....More>>>

Hot Bank Stocks To Watch Right Now

Citigroup restated their buy rating on shares of Johnson Matthey (LON:JMAT) in a report issued on Tuesday morning.

A number of other research analysts have also recently issued reports on the company. Credit Suisse Group reissued an outperform rating on shares of Johnson Matthey in a report on Friday, May 4th. Morgan Stanley reissued an overweight rating on shares of Johnson Matthey in a report on Wednesday, March 28th. JPMorgan Chase & Co. reissued a neutral rating and set a GBX 3,400 ($45.62) price objective on shares of Johnson Matthey in a report on Thursday, March 8th. Liberum....More>>>

Best Heal Care Stocks To Buy For 2019

Lets face it: budgeting is a real pain. Thats why Andrew Sivertsen, a partner and senior financial planner in the Quad Cities office of The Planning Center, advocates another way to control your money. A much easier way. His prescription:  

Just saying the word budget is enough to cause your gut to wrench and make you feel guilty.  Many academics and journalists have told us that a budget is the cornerstone of financial success.  Yet according to a recent Gallup poll, two thirds of Americans dont have a budget, and I would guess that the one third that....More>>>

Top 10 Heal Care Stocks To Invest In Right Now

Celgene Corp. (NASDAQ:CELG) investors would probably like a few do-overs given the company’s stumbles over the past year. First, it suffered a key clinical-trial failure that forced it to ratchet back its long-term sales outlook. Then, the FDA sent it an embarrassing Refusal to File letter for its most-anticipated drug, ozanimod.

The setbacks have increased the pressure on the company to deliver a win, and fortunately, that win came in the form of positive pivotal-stage trial results for luspatercept, a drug that Celgene has licensed from Acceleron Pharma (NASDAQ:XLRN). On Thursday,....More>>>

Top 10 Heal Care Stocks To Buy Right Now

After examining Walt Disney’s (DIS) earnings, which were released after yesterday’s market close, Stifel’s Benjamin Mogil and Kevin Lee Hon Siong argued that they “continue to view Disney as a Tale of Two Stories.” They explain why:

Getty Images

Disney reported 4Q16 results which were in-line with our estimates but below those of consensus expectations. Commentary for 2017 was likely below expectations but at the same set the stage for more realistic expectations and we view that clarity/transparency as one of the bigger factors behind the after-market....More>>>